941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.
暂无分享,去创建一个
B. Monk | A. Oza | R. Wenham | D. Katsaros | J. Ledermann | J. Berek | I. Vergote | U. Matulonis | R. Martell | M. Mirza | C. Marth | M. Fabbro | J. Herrstedt | S. Mahner | D. Lorusso | A. Dørum | S. Agarwal | J. D. Del Campo | I. Bruchim | S. Malander